The ATB200-02 study is an international, multi-center, study in adult subjects with Pompe disease. The purpose of this study is to find out if AT2221 can be safely used with ATB200 and will increase ATB200 in the bloodstream.


The Stride study is designed to collect information about patients with late-onset Pompe (LOPD) disease who are already treated with enzyme replacement therapy (ERT).